Skip to content

    Melanoma/Skin Cancer Health Center

    Font Size
    A
    A
    A

    Zelboraf May Double Survival for Some Melanoma Patients

    New Drug Extends Life, Lessens Pain for Many Patients With Common Form of Advanced Melanoma

    Drug May Buy Patients More Time continued...

    The study was paid for by Hoffmann-La Roche, the company that makes the drug.

    In addition to giving patients more time, researchers say the drug, which costs about $9,400 a month, helps people feel better for longer.

    “We get some great responses initially, at least, so we can talk to patients with a smile compared to two years ago; it was a pretty much pessimistic view of the outcomes,” says researcher Kevin B. Kim, MD, an associate professor of melanoma medical oncology at The University of Texas MD Anderson Cancer Center in Houston.

    For patients with large tumors who are suffering from pain and discomfort, “We can shrink tumors significantly, so the pain can be improved quite dramatically,” Kim says. “People feel stronger very quickly.”

    Side Effects ‘Not Trivial’

    Along with those benefits, the drug does come with some significant side effects.

    “The side effects are certainly reasonable for a cancer drug. They’re not trivial,” Sosman says. “A number of patients needed to have their drug held for a short time or needed to have their dose lowered, but almost all patients continued on the drug. Few stopped it.”

    The most problems seen in patients taking the drug were joint pain, rash, skin that easily burns in the sun, fatigue, and hair loss. More than a quarter of patients who take the drug also develop new squamous-cell skin cancers, although those are thought to be less dangerous than the melanoma.

    “These patients should be followed closely by a dermatologist, which is probably a good idea anyway,” Sosman says.

    Experts who were not involved in the study said the results mark an important advance in treating melanoma, but noted that there was much more work to be done to understand why people develop resistance to the drug and eventually relapse.

    “This is a very exciting drug in the sense that it provides almost all patients with BRAF-mutated melanomas a remission,” says Kim A. Margolin, MD, who leads melanoma research for the Seattle Cancer Care Alliance.

    “There’s no remote chance this is going to be a cure. There may be 1% or 2% of patients who remain in very durable remissions, but everyone is scratching their heads about why they haven’t developed resistance the way everyone else has,” says Margolin, who is also a professor at the University of Washington and a member of the Fred Hutchinson Cancer Research Center, both in Seattle.

    Today on WebMD

    Malignant melanoma
    How to spot it early.
    Woman checking out tan lines
    There’s a dark side to that strive for beauty.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    12 Ways to Protect Your Skin from Melanoma
    ARTICLE
    precancerous lesions slideshow
    SLIDESHOW
     
    Do You Know Your Melanoma ABCs
    VIDEO
    15 Cancer Symptoms Men Ignore
    ARTICLE
     
    screening tests for men
    SLIDESHOW
    Vitamin D
    SLIDESHOW
     
    Is That Mole Skin Cancer
    VIDEO
    Brilliant sun rays
    Quiz